title: Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
abstract: Proliferative vitreoretinopathy (PVR) is a blinding disorder that occurs in eyes with rhegmatogenous retinal detachment and in eyes that have recently undergone retinal detachment surgery. There are presently no treatment strategies to reduce the risk of developing PVR in eyes with retinal detachment, and surgical intervention is the only option for eyes with retinal detachment and established PVR. Given the poor visual outcome associated with the surgical treatment of PVR, considerable work has been done to identify pharmacologic agents that could antagonize the PVR process. Intensive efforts to identify molecular determinants of PVR implicate vitreal growth factors. A surprise that emerged in the course of testing the 'growth factor hypothesis' of PVR was the existence of a functional relationship amongst growth factors that engage platelet-derived growth factor (PDGF) receptor α (PDGFRα), a receptor tyrosine kinase that is key to pathogenesis of experimental PVR. Vascular endothelial cell growth factor A (VEGF), which is best known for its ability to activate VEGF receptors (VEGFRs) and induce permeability and/or angiogenesis, enables activation of PDGFRα by a wide spectrum of vitreal growth factors outside of the PDGF family (non-PDGFs) in a way that triggers signaling events that potently enhance the viability of cells displaced into vitreous. Targeting these growth factors or signaling events effectively neutralizes the bioactivity of PVR vitreous and prevents PVR in a number of preclinical models. In this review, we discuss recent conceptual advances in understanding the role of growth factors in PVR, and consider the tangible treatment strategies for clinical application.
authors.affiliation: The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Pennock
authors.affiliation: The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Luis J
authors.initials: LJ
authors.lastname: Haddock
authors.affiliation: The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Dean
authors.initials: D
authors.lastname: Eliott
authors.affiliation: The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Shizuo
authors.initials: S
authors.lastname: Mukai
authors.affiliation: The Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA. Electronic address: andrius_kazlauskas@meei.harvard.edu.
authors.forename: Andrius
authors.initials: A
authors.lastname: Kazlauskas
mesh_terms: D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000502:physiology*; D012307:Risk Factors; D018630:Vitreoretinopathy, Proliferative / Q000378:metabolism* / Q000517:prevention & control; D014822:Vitreous Body / Q000502:physiology*
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D020796:Receptor, Platelet-Derived Growth Factor alpha
keywords: Growth factors; PDGFR; Proliferative vitreoretinopathy; Retinal detachment; Signaling; Vitreous